Home > Insider Trading > Filing (0001610717-25-000031)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1885522	Neumora Therapeutics Inc.	NMRA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1202769	L Paul Berns	C/O Neumora Therapeutics, Inc. 490 Arsenal Way, Suite 200 Watertown MA 02472	See Remarks	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-02-18	13,871	$1.69	7,405,004	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	133,097	Indirect	See footnote
Common Stock	133,097	Indirect	See footnote
Common Stock	133,097	Indirect	See footnote

Footnotes

The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 19, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation.
This transaction was executed in multiple trades in prices ranging from $1.66 to $1.745, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Held by LULU TRUST OF 2024 FBO AB.
Held by LULU TRUST OF 2024 FBO OB.
Held by LULU TRUST OF 2024 FBO HB.